Protocol: Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study (28 May, 2021)
Nirosen Vijiaratnam, Christine Girges, Grace Auld, Marisa Chau, Kate Maclagan, Alexa King, Simon Skene, Kashfia Chowdhury, Steve Hibbert, Huw Morris, Patricia Limousin, Dilan Athauda, Camille B Carroll, Michele T Hu, Monty Silverdale, Gordon W Duncan, Ray Chaudhuri, Christine Lo, Silvia Del Din, Alison J Yarnall, Lynn Rochester, Rachel Gibson, John Dickson, Rachael Hunter, Vincenzo Libri, Thomas Foltynie